Clinical trials: Recurrent GBM
Recurrent Glioblastoma (WHO-Grade IV Glioma)
Clinical Trial on the Combination of Avelumab and Axitinib for the Treatment of Patients With Recurrent Glioblastoma
Phase II clinical trial on the combination of avelumab and axitinib for the treatment of patients with recurrent glioblastoma (histologically confirmed WHO grade IV glioma), at documented recurrence/progression following prior…
- Trial name
- GliAvAx (NCT03291314)
- Testing
- Axitinib, Avelumab
- Where
- Belgium
- Volunteers
- 52 people
- Sponsor
- Universitair Ziekenhuis Brussel
Brain and Central Nervous System Tumors
Lapatinib in Treating Patients With Recurrent Glioblastoma Multiforme
RATIONALE: Lapatinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. PURPOSE: This phase I/II trial is studying the side effects and best dose of lapatinib and to see how well it works in…
- Trial name
- NCT00099060
- Testing
- lapatinib ditosylate
- Where
- 6 sites in Canada
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Glioblastoma, Newly Diagnosed MGMT Unmethylated Glioblastoma
OLIG2 Inhibitor CT-179 for Recurrent and Newly-diagnosed Glioblastoma
This is a first-in-human Phase 1 two-part, open-label, multi-center, dose escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and maximum tolerated dose (MTD) of CT-179 in…
- Trial name
- OPAL (NCT07739017)
- Testing
- CT-179
- Where
- 6 sites in Australia
- Volunteers
- 54 people
- Sponsor
- Olivia Newton-John Cancer Research Institute
Brain and Central Nervous System Tumors
Imatinib Mesylate and Temozolomide in Treating Patients With Malignant Glioma
RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells…
- Trial name
- NCT00354068
- Testing
- imatinib mesylate, temozolomide, pharmacological study
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Duke University
Recurrent Glioblastoma
Ketogenic Diet for Recurrent Glioblastoma
To determine whether a mild ketogenic diet can influences quality of life and survival of patients with recurrent glioblastoma
- Trial name
- ERGO (NCT00575146)
- Testing
- TAVARLIN
- Where
- 2 sites in Germany
- Volunteers
- 20 people
- Sponsor
- University Hospital Tuebingen
Brain and Central Nervous System Tumors, Lymphoma
Pemetrexed Disodium in Treating Patients With Recurrent Malignant Gliomas, Primary CNS Lymphoma, or Brain Metastases
RATIONALE: Pemetrexed disodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well pemetrexed disodium works in treating patients with…
- Conditions
- Brain and Central Nervous System Tumors, Lymphoma, Metastatic Cancer
- Trial name
- NCT00276783
- Testing
- pemetrexed
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- Northwestern University
Glioblastoma Multiforme
Pilot Study of Autologous Anti-EGFRvIII CAR T Cells in Recurrent Glioblastoma Multiforme
Chimeric antigen receptor (CAR)-modified T cells can mediate long-term durable remissions in recurrent or refractory CD19+ B cell malignancies, and are a promising therapy to treat glioblastoma, which is the most dangerous and…
- Trial name
- NCT02844062
- Testing
- anti-EGFRvIII CAR T cells, cyclophosphamide, Fludarabine
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Beijing Sanbo Brain Hospital
Brain and Central Nervous System Tumors
Topotecan and Thalidomide in Treating Patients With Recurrent or Refractory Malignant Glioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor.
- Trial name
- NCT00014443
- Testing
- thalidomide, topotecan hydrochloride
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Rush University Medical Center
Anaplastic Astrocytoma, Glioblastoma
A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and Glioblastoma
We are asked patients to take part in this study because they had recurrent (returned) (1st or 2nd) anaplastic astrocytoma (AA) or glioblastoma multiforme (GBM).
- Trial name
- NCT00606008
- Testing
- Sunitinib Malate
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Adult Giant Cell Glioblastoma, Adult Glioblastoma
Neoadjuvant and Adjuvant Fenretinide Compared With Adjuvant Fenretinide Alone in Treating Patients Who Are Undergoing Surgical Resection For Recurrent Glioblastoma Multiforme
This randomized phase II trial is studying how well neoadjuvant and adjuvant fenretinide works compared to adjuvant fenretinide alone in treating patients who are undergoing surgical resection for recurrent glioblastoma…
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
- Trial name
- NCT00075491
- Testing
- fenretinide, therapeutic conventional surgery, pharmacological study
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- National Cancer Institute (NCI)
Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma
Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma
This phase I trial studies the side effects of vaccine therapy when given together with sargramostim in treating patients with malignant glioma.
- Conditions
- Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Giant Cell Glioblastoma
- Trial name
- NCT01250470
- Testing
- Laboratory Biomarker Analysis, Montanide ISA-51/Survivin Peptide Vaccine, Sargramostim
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Roswell Park Cancer Institute
Glioblastoma, Malignant Glioma
Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults
This phase I trial studies the side effects of nivolumab before and after surgery in treating children and young adults with high grade glioma that has come back (recurrent) or is increasing in scope or severity (progressive).
- Conditions
- Glioblastoma, Malignant Glioma, Recurrent Glioblastoma, Recurrent Malignant Glioma
- Trial name
- NCT04323046
- Testing
- Nivolumab, Quality-of-Life Assessment, Questionnaire Administration
- Where
- 20 sites in United States, Australia
- Volunteers
- 9 people
- Sponsor
- Sabine Mueller, MD, PhD
Glioma
Pharmacokinetics (PK) Study of AC480 for Recurrent Glioma
The primary objective is to evaluate the intratumoral and plasma pharmacokinetics of AC480 among patients who are candidates for a resection with a recurrent malignant glioma who are not on CYP-3A enzyme inducing anti-epileptic…
- Trial name
- NCT00979173
- Testing
- AC480
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Annick Desjardins
Glioblastoma Multiforme
131I-IPA and Concurrent XRT in Recurrent GBM
A multi-centre, open-label, single-arm, dose-finding phase I/II study to evaluate safety, tolerability, dosing schedule, and preliminary efficacy of carrier-added 4-L-[131I]iodo-phenylalanine (131I-IPA), administered as single or…
- Trial name
- IPAX-1 (NCT03849105)
- Testing
- 4-L-[131I]iodo-phenylalanine (131I-IPA)
- Where
- 5 sites in Australia, Austria and 1 more
- Volunteers
- 10 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma
Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
This phase I trial studies the side effects and best schedule of vaccine therapy with or without sirolimus in treating patients with cancer-testis antigen (NY-ESO-1) expressing solid tumors.
- Conditions
- Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Estrogen Receptor Negative
- Trial name
- NCT01522820
- Testing
- DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Roswell Park Cancer Institute
Glioblastoma, Anaplastic Astrocytoma
Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma
In this multinational dose finding Phase IIb study the efficacy and safety of two doses of AP 12009 compared to standard chemotherapy (temozolomide or PCV) is investigated in adult patients with confirmed recurrent high-grade…
- Trial name
- NCT00431561
- Testing
- AP 12009 10 µM, AP 12009 80 µM, temozolomide or PCV
- Where
- 36 sites in Austria, Georgia and 4 more
- Volunteers
- 141 people
- Sponsor
- Isarna Therapeutics GmbH
Glioblastoma Multiforme
A Study of Temsirolimus and Bevacizumab in Recurrent Glioblastoma Multiforme
This trial is an investigator initiated, open label phase II study, where patient with recurrent primary GBM will be considered for the study.
- Trial name
- NCT00800917
- Testing
- Temsirolimus, Bevacizumab
- Where
- Denmark
- Volunteers
- 12 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Glioblastoma Multiforme, Anaplastic Astrocytoma
INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas
This is a multicenter phase 1 trial of INCB7839 for children with recurrent or progressive high-grade gliomas, including, but not limited to, diffuse intrinsic pontine glioma (DIPG) and other diffuse midline gliomas (DMGs), after…
- Conditions
- Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, DIPG
- Trial name
- NCT04295759
- Testing
- INCB7839
- Where
- 11 sites in United States
- Volunteers
- 13 people
- Sponsor
- Pediatric Brain Tumor Consortium
Malignant Glioma
Phase 2 Study of Sym004 for Adult Patients With Recurrent Glioblastoma
The purpose of this study is to assess the activity of Sym004, a recombinant antibody mixture that specifically binds to EGFR, in patients diagnosed with recurrent glioblastoma whose tumor is EGFR amplified.
- Trial name
- NCT02540161
- Testing
- Sym004 - 18 mg/kg, Sym004 - 24 mg/kg
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Annick Desjardins
Brain and Central Nervous System Tumors
Monoclonal Antibody Therapy in Treating Patients With Recurrent Gliomas
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00002753
- Testing
- iodine I 131 monoclonal antibody 81C6
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Duke University